Roche COVID-19 Response | Questions About Our Medicines? Visit medinfo.roche.com
Erlotinib clinical trials
Erlotinib is a selective, reversible tyrosine kinase inhibitor which binds with high affinity to the mutated EGFR receptor, thus preventing promotion of tumour cell survival and proliferation.1
Please click below for more information on the key clinical trials that demonstrate
erlotinib's safety and efficacy profile in the first-line treatment of EGFR Mut+ NSCLC.
References
- Planchard, et al. Ann Oncol 2018; 29(Supplement_4):iv192-iv237.
- NCCN NSCLC Guidelines V4 2019;
- Chinese Society of Clinical Oncology, 2019 www.csco.org.cn
Data of preparation February 2020- M-XX-00000785 - © 2020
This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) the United Kingdom (UK), and Australia (AU) who are interested in information on TARCEVA®. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.